236 related articles for article (PubMed ID: 26823915)
1. Differential proteomics analysis of mononuclear cells in cerebrospinal fluid of Parkinson's disease.
Xing L; Wang D; Wang L; Lan W; Pan S
Int J Clin Exp Pathol; 2015; 8(11):15462-6. PubMed ID: 26823915
[TBL] [Abstract][Full Text] [Related]
2. Identification of differentially displayed proteins in cerebrospinal fluid of Parkinson's disease patients: a proteomic approach.
Sinha A; Srivastava N; Singh S; Singh AK; Bhushan S; Shukla R; Singh MP
Clin Chim Acta; 2009 Feb; 400(1-2):14-20. PubMed ID: 18977210
[TBL] [Abstract][Full Text] [Related]
3. Cerebrospinal fluid proteomic patterns discriminate Parkinson's disease and multiple system atrophy.
Ishigami N; Tokuda T; Ikegawa M; Komori M; Kasai T; Kondo T; Matsuyama Y; Nirasawa T; Thiele H; Tashiro K; Nakagawa M
Mov Disord; 2012 Jun; 27(7):851-7. PubMed ID: 22674850
[TBL] [Abstract][Full Text] [Related]
4. Deployment of Label-Free Quantitative Olfactory Proteomics to Detect Cerebrospinal Fluid Biomarker Candidates in Synucleinopathies.
Lachén-Montes M; González-Morales A; Fernández-Irigoyen J; Santamaría E
Methods Mol Biol; 2019; 2044():273-289. PubMed ID: 31432419
[TBL] [Abstract][Full Text] [Related]
5. Proteomic analysis of the cerebrospinal fluid of patients with schizophrenia.
Jiang L; Lindpaintner K; Li HF; Gu NF; Langen H; He L; Fountoulakis M
Amino Acids; 2003 Jul; 25(1):49-57. PubMed ID: 12836058
[TBL] [Abstract][Full Text] [Related]
6. Proteomic identification of biomarkers in the cerebrospinal fluid in a rat model of nigrostriatal dopaminergic degeneration.
Rite I; Argüelles S; Venero JL; García-Rodriguez S; Ayala A; Cano J; Machado A
J Neurosci Res; 2007 Dec; 85(16):3607-18. PubMed ID: 17705290
[TBL] [Abstract][Full Text] [Related]
7. A proteomic approach in the study of an animal model of Parkinson's disease.
De Iuliis A; Grigoletto J; Recchia A; Giusti P; Arslan P
Clin Chim Acta; 2005 Jul; 357(2):202-9. PubMed ID: 15946658
[TBL] [Abstract][Full Text] [Related]
8. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients.
Guo J; Sun Z; Xiao S; Liu D; Jin G; Wang E; Zhou J; Zhou J
Cell Res; 2009 Dec; 19(12):1401-3. PubMed ID: 19949427
[No Abstract] [Full Text] [Related]
9. Diagnostic cerebrospinal fluid biomarkers for Parkinson's disease: a pathogenetically based approach.
van Dijk KD; Teunissen CE; Drukarch B; Jimenez CR; Groenewegen HJ; Berendse HW; van de Berg WD
Neurobiol Dis; 2010 Sep; 39(3):229-41. PubMed ID: 20451609
[TBL] [Abstract][Full Text] [Related]
10. Proteome analysis of human substantia nigra in Parkinson's disease.
Basso M; Giraudo S; Corpillo D; Bergamasco B; Lopiano L; Fasano M
Proteomics; 2004 Dec; 4(12):3943-52. PubMed ID: 15526345
[TBL] [Abstract][Full Text] [Related]
11. Tetranectin and apolipoprotein A-I in cerebrospinal fluid as potential biomarkers for Parkinson's disease.
Wang ES; Sun Y; Guo JG; Gao X; Hu JW; Zhou L; Hu J; Jiang CC
Acta Neurol Scand; 2010 Nov; 122(5):350-9. PubMed ID: 20085559
[TBL] [Abstract][Full Text] [Related]
12. Cerebrospinal fluid proteomics and human immunodeficiency virus dementia: preliminary observations.
Berger JR; Avison M; Mootoor Y; Beach C
J Neurovirol; 2005 Dec; 11(6):557-62. PubMed ID: 16338749
[TBL] [Abstract][Full Text] [Related]
13. Between-gel reproducibility of the human cerebrospinal fluid proteome.
Terry DE; Desiderio DM
Proteomics; 2003 Oct; 3(10):1962-79. PubMed ID: 14625859
[TBL] [Abstract][Full Text] [Related]
14. Cytotoxicity of ventricular cerebrospinal fluid from Parkinson patients: correlation with clinical profiles and neurochemistry.
Mandybur GT; Miyagi Y; Yin W; Perkins E; Zhang JH
Neurol Res; 2003 Jan; 25(1):104-11. PubMed ID: 12564136
[TBL] [Abstract][Full Text] [Related]
15. Proteomic analysis of the cerebrospinal fluid of Parkinson's disease patients pre- and post-deep brain stimulation.
Wang ES; Yao HB; Chen YH; Wang G; Gao WW; Sun YR; Guo JG; Hu JW; Jiang CC; Hu J
Cell Physiol Biochem; 2013; 31(4-5):625-37. PubMed ID: 23652646
[TBL] [Abstract][Full Text] [Related]
16. Elemental fingerprint as a cerebrospinal fluid biomarker for the diagnosis of Parkinson's disease.
Maass F; Michalke B; Leha A; Boerger M; Zerr I; Koch JC; Tönges L; Bähr M; Lingor P
J Neurochem; 2018 May; 145(4):342-351. PubMed ID: 29388213
[TBL] [Abstract][Full Text] [Related]
17. [Proteomics study on the essence of wind syndrome caused by gan-yang hyperactivity in Chinese medicine].
Xiong XG; Chen J; Liang QH
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2011 Jul; 31(7):913-20. PubMed ID: 21866661
[TBL] [Abstract][Full Text] [Related]
18. Applying bioinformatics to proteomics: is machine learning the answer to biomarker discovery for PD and MSA?
Mattison HA; Stewart T; Zhang J
Mov Disord; 2012 Nov; 27(13):1595-7. PubMed ID: 23115026
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of potential protein markers in cerebrospinal fluid of GBS patients.
Jin T; Hu LS; Chang M; Wu J; Winblad B; Zhu J
Eur J Neurol; 2007 May; 14(5):563-8. PubMed ID: 17437617
[TBL] [Abstract][Full Text] [Related]
20. Proteomics of brain extracellular fluid (ECF) and cerebrospinal fluid (CSF).
Maurer MH
Mass Spectrom Rev; 2010; 29(1):17-28. PubMed ID: 19116946
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
